GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2009

Alpco to Market Athera’s Cardiovascular Biomarker ELISA Kit in North America

  • Alpco negotiated North American distribution rights to Swedish company Athera’s CVDefine® research-use ELISA kit for the quantitative analysis of anti-PC in human blood. The cardiovascular disease biomarker test has been developed to help the early detection of lesions in the artery wall caused by inflammation. A CE-marked CVDefine kit is available in Europe.
    CVDefine is the first product in Athera’s diagnostic pipeline.

    The company, part of the Karolinska Development portfolio, is focused on developing novel products for the treatment and prevention of cardiovascular disease.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?